Hanmi Pharmaceutical has terminated its contract with Genexine to produce COVID-19 vaccines

This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology

폴리

hoondork1977@alphabiz.co.kr | 2023-02-28 05:30:50

서울 송파구 방이동 한미약품 본사 (사진 = 연합뉴스)

[Alpha Biz=(Chicago) Reporter Paul Lee] Hanmi Pharmaceutical announced on the 27th that it has agreed to terminate the contract for consignment production of Genexine COVID-19 vaccines.

According to the public announcement, the main reason for the termination of the contract is Genexine's decision to stop developing the COVID-19 vaccine.

With the termination of the contract, the amount of termination is 23.4 billion won, excluding performance performance from the existing contract amount.

 

 


[ⓒ AlphaBIZ. 무단전재-재배포 금지]

많이 본 기사